895 related articles for article (PubMed ID: 28490016)
1. Backup Mechanisms Maintain PACAP/VIP-Induced Arterial Relaxations in Pituitary Adenylate Cyclase-Activating Polypeptide-Deficient Mice.
Ivic I; Fulop BD; Juhasz T; Reglodi D; Toth G; Hashimoto H; Tamas A; Koller A
J Vasc Res; 2017; 54(3):180-192. PubMed ID: 28490016
[TBL] [Abstract][Full Text] [Related]
2. Aging-Induced Modulation of Pituitary Adenylate Cyclase-Activating Peptide- and Vasoactive Intestinal Peptide-Induced Vasomotor Responses in the Arteries of Mice.
Ivic I; Solymar M; Fulop BD; Hashimoto H; Toth G; Tamas A; Juhasz T; Koller A; Reglodi D
J Vasc Res; 2017; 54(6):359-366. PubMed ID: 29131060
[TBL] [Abstract][Full Text] [Related]
3. VPAC1 receptors play a dominant role in PACAP-induced vasorelaxation in female mice.
Ivic I; Balasko M; Fulop BD; Hashimoto H; Toth G; Tamas A; Juhasz T; Koller A; Reglodi D; Solymár M
PLoS One; 2019; 14(1):e0211433. PubMed ID: 30682157
[TBL] [Abstract][Full Text] [Related]
4. PACAP and its receptors in cranial arteries and mast cells.
Jansen-Olesen I; Hougaard Pedersen S
J Headache Pain; 2018 Feb; 19(1):16. PubMed ID: 29460121
[TBL] [Abstract][Full Text] [Related]
5. Stimulatory effect of pituitary adenylate cyclase-activating polypeptide 6-38, M65 and vasoactive intestinal polypeptide 6-28 on trigeminal sensory neurons.
Sághy É; Payrits M; Helyes Z; Reglődi D; Bánki E; Tóth G; Couvineau A; Szőke É
Neuroscience; 2015 Nov; 308():144-56. PubMed ID: 26321242
[TBL] [Abstract][Full Text] [Related]
6. A cloned frog vasoactive intestinal polypeptide/pituitary adenylate cyclase-activating polypeptide receptor exhibits pharmacological and tissue distribution characteristics of both VPAC1 and VPAC2 receptors in mammals.
Alexandre D; Anouar Y; Jegou S; Fournier A; Vaudry H
Endocrinology; 1999 Mar; 140(3):1285-93. PubMed ID: 10067855
[TBL] [Abstract][Full Text] [Related]
7. Expression localisation and functional activity of pituitary adenylate cyclase-activating polypeptide, vasoactive intestinal polypeptide and their receptors in mouse ovary.
Barberi M; Muciaccia B; Morelli MB; Stefanini M; Cecconi S; Canipari R
Reproduction; 2007 Aug; 134(2):281-92. PubMed ID: 17660238
[TBL] [Abstract][Full Text] [Related]
8. Pituitary adenylate cyclase-activating polypeptide receptors mediating insulin secretion in rodent pancreatic islets are coupled to adenylate cyclase but not to PLC.
Jamen F; Puech R; Bockaert J; Brabet P; Bertrand G
Endocrinology; 2002 Apr; 143(4):1253-9. PubMed ID: 11897681
[TBL] [Abstract][Full Text] [Related]
9. VPAC2-R mediates the lipolytic effects of pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide in primary rat adipocytes.
Akesson L; Ahrén B; Edgren G; Degerman E
Endocrinology; 2005 Feb; 146(2):744-50. PubMed ID: 15514088
[TBL] [Abstract][Full Text] [Related]
10. Pituitary adenylate cyclase-activating polypeptide ameliorates vascular dysfunction induced by hyperglycaemia.
Solymar M; Ivic I; Balasko M; Fulop BD; Toth G; Tamas A; Reman G; Koller A; Reglodi D
Diab Vasc Dis Res; 2018 Jul; 15(4):277-285. PubMed ID: 29466879
[TBL] [Abstract][Full Text] [Related]
11. Characterization of intestinal receptors for VIP and PACAP in rat and in PAC1 receptor knockout mouse.
Ekblad E; Jongsma H; Brabet P; Bockaert J; Sundler F
Ann N Y Acad Sci; 2000; 921():137-47. PubMed ID: 11193817
[TBL] [Abstract][Full Text] [Related]
12. PACAP-38 but not VIP induces release of CGRP from trigeminal nucleus caudalis via a receptor distinct from the PAC1 receptor.
Jansen-Olesen I; Baun M; Amrutkar DV; Ramachandran R; Christophersen DV; Olesen J
Neuropeptides; 2014 Apr; 48(2):53-64. PubMed ID: 24508136
[TBL] [Abstract][Full Text] [Related]
13. Pituitary adenylate cyclase-activating polypeptide and PACAP receptor expression and function in the rat adrenal gland.
Mazzocchi G; Malendowicz LK; Neri G; Andreis PG; Ziolkowska A; Gottardo L; Nowak KW; Nussdorfer GG
Int J Mol Med; 2002 Mar; 9(3):233-43. PubMed ID: 11836629
[TBL] [Abstract][Full Text] [Related]
14. PAC1 receptors mediate pituitary adenylate cyclase-activating polypeptide- and progesterone-facilitated receptivity in female rats.
Apostolakis EM; Riherd DN; O'Malley BW
Mol Endocrinol; 2005 Nov; 19(11):2798-811. PubMed ID: 15976009
[TBL] [Abstract][Full Text] [Related]
15. All D-VIP mitigates vasodilation elicited by L-VIP, micellar L-VIP and micellar PACAP1-38, but not PACAP1-38, in vivo.
Rubinstein I; Ashok B; Tsueshita T; Onyüksel H
Peptides; 2005 Mar; 26(3):509-15. PubMed ID: 15652658
[TBL] [Abstract][Full Text] [Related]
16. PACAP and VIP prevent apoptosis in schwannoma cells.
Castorina A; Tiralongo A; Giunta S; Carnazza ML; Rasi G; D'Agata V
Brain Res; 2008 Nov; 1241():29-35. PubMed ID: 18835258
[TBL] [Abstract][Full Text] [Related]
17. Characterization and expression of different pituitary adenylate cyclase-activating polypeptide/vasoactive intestinal polypeptide receptors in rat ovarian follicles.
Vaccari S; Latini S; Barberi M; Teti A; Stefanini M; Canipari R
J Endocrinol; 2006 Oct; 191(1):287-99. PubMed ID: 17065411
[TBL] [Abstract][Full Text] [Related]
18. [Physiological significance of pituitary adenylate cyclase-activating polypeptide (PACAP) in the nervous system].
Hashimoto H
Yakugaku Zasshi; 2002 Dec; 122(12):1109-21. PubMed ID: 12510388
[TBL] [Abstract][Full Text] [Related]
19. VIP and PACAP effects on mouse major pelvic ganglia neurons.
Tompkins JD; Girard BM; Vizzard MA; Parsons RL
J Mol Neurosci; 2010 Nov; 42(3):390-6. PubMed ID: 20428965
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological characterization of VIP and PACAP receptors in the human meningeal and coronary artery.
Chan KY; Baun M; de Vries R; van den Bogaerdt AJ; Dirven CM; Danser AH; Jansen-Olesen I; Olesen J; Villalón CM; MaassenVanDenBrink A; Gupta S
Cephalalgia; 2011 Jan; 31(2):181-9. PubMed ID: 20974589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
